Tumor angiogenesis: A physiological process or genetically determined?

Cancer and Metastasis Reviews

Volumn 15, Issue 2, 1996, Pages 205-212

  D'Amore, Patricia A ^a   Shima, David T ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Hypoxia; Neovascularization; Oncogenes; Tumor suppressors; Vascular endothelial growth factor

Indexed keywords

FIBROBLAST GROWTH FACTOR; VASCULOTROPIN;

ANGIOGENESIS; CELL INTERACTION; CELL SURVIVAL; INFLAMMATION; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; REVIEW; TISSUE GROWTH; TUMOR GROWTH; VASCULARIZATION;

ANIMALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0030059452     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00437473     Document Type: Review

References (36)

1. Folkman J: Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175: 409-416, 1972
2. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844, 1993
3. Millauer B, Shawver LK, Risau W, Ullrich A: Glioblastoma growth inhibited in viva by a dominant-negative Flk-1 mutant. Nature 367: 576-579, 1994
4. Warren RS, Yuan H, Matli MR, Gillett N, Ferrara N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95: 1789-1797, 1995
5. Stone J, Itin A, Alon T, Pe'er J, Gnessin H, Chan-Ling T, Keshet E: Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 15: 4738-4747, 1995
6. Hudlicka O: Development and adaptability of microvasculature in skeletal muscle. J Exp Biol 115: 215-228, 1985
7. Hudlicka O, Brown M, Egginton S: Angiogenesis in skeletal and cardiac muscle. Physiol Rev 72: 369-417, 1992
8. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992
9. Shima DT, Adamis AP, Yeo K-T, Yeo T-K, Allende R, Folkman J, D'Amore PA: Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1: 182-193, 1995
10. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848, 1992
11. Shweiki D, Neeman M, Itin A, Keshet E: Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implication for tumor angiogenesis. Proc Natl Acad Sci USA 92: 768-772, 1995
12. Dvorak H, Brown L, Detmar M, Dvorak A: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Path 146: 1029-1038, 1995
13. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LEH: Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 92: 905-909, 1995
14. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D'Amore PA, Miller JW: Inhibition of VEGF prevents ocular neovascularization in a primate. Arch Ophthalmol 114: 66-71, 1996
15. Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, et al.: Vascular permeability factor/vascular endothelial cell growth factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 145: 574-584, 1994
16. D'Amore PA: Mechanisms of endothelial growth control. Am J Respir Cell Mol Biol 6: 1-8, 1992
17. Folkman J: Angiogenesis inhibitors generated by tumors. Mol Med 1: 120-122, 1996
18. Christofori G, Hanahan D: Molecular dissection of multistage tumorigenesis in transgenic mice. Semin Cancer Biol 5: 3-21, 1994
19. Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66: 1095-1104, 1991
20. Dietrich WF, Radany EH, Smith JS, Bishop JM, Hanahan D, Lander ES: Genome-wide search for loss of heterozygosity in transgenic mouse tumors reveals candidate tumor suppressor genes on chromosomes 9 and 16. Proc Natl Acad Sci USA 91: 9451-9455, 1994
21. Rastinejad F, Polverini PJ, Bouck NP: Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 56: 345-355, 1989
22. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP: A tumor suppressor dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87: 6624-6628, 1990
23. Dameron KM, Volpert OV, Tainsky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584, 1994
24. RayChaudhury A, Frazier WA, D'Amore PA: Comparison of normal and tumorigenic endothelial cells: differences in thrombospondin production and responses to transforming growth factor-beta. J Cell Sci 107: 39-46, 1994
25. Sheibani N, Frazier WA: Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc Natl Acad Sci USA 92: 6788-6792, 1995
26. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS: Oncogenes as inducers of tumor angiogenesis. Cancer Met Rev 14: 263-277, 1995
27. Grugel S, Finkenzeller G, Weindel K, Barleon B, Marme D: Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cell. J Biol Chem 270: 25915-25919, 1995
28. Rak J, Bayko L, Filmus J, Shirasawa S, Kerber RS: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575-4580, 1995
29. Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo K-T, Manseau EL, Dvorak HF: Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 56: 172-196, 1996
30. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: balanced proliferation and apoplosis in the presence of angiogenesis suppression. Nature Med 1: 149-153, 1995
31. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Med 1: 27-31, 1995
32. Antonelli-Orlidge A, Saunders KB, Smith SR, D'Amore PA: An activated form of TGF-β is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 86: 4544-4548, 1989
33. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 315-328, 1944
34. Lu C, Kerbel RS: Cytokines, growth factors and the loss of negative growth control in the progression of human cutaneous malignant melanoma. Curr Opin Oncol 6: 212-220, 1994
35. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giacca AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379: 88-90, 1996
36. Kinzler KW, Vogelstein B: Life (and death) in a malignant tumor. Nature 73: 19-20, 1996